An observational study in Breast Cancer, sponsored by Banaras Hindu University. Completed at 1 site in India. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-08-13.
Sponsored by Banaras Hindu University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 182 studies in Breast Neoplasms with a site in India — 20 open to participants now, 53 under way, 37 of them phase 3. Breast Neoplasms · India.
Among the 182 studies in Breast Neoplasms with a site in India, this one is the 13th largest by enrollment of the 19 observational ones that give a count, is one of 16 that started in 2021, is one of 19 observational ones, and was the 147th registered.
14,848 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →20 of the 182 studies in Breast Neoplasms with a site in India are open now. Recruiting first, the newest first:
Natureceuticals Sdn Bhd · Sites in India
Ages 18–65 · Women only
Bristol-Myers Squibb · Sites in India, United States, Argentina and 25 more countries
Ages 18+
All India Institute of Medical Sciences, Bhubaneswar · Sites in India
Ages 18–75 · Women only
Pfizer · Sites in India, United States, Argentina and 28 more countries
Ages 18–99
Merck Sharp & Dohme LLC · Sites in India, United States, Argentina and 38 more countries
Ages 18+
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 99 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
182 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 44 · Phase 3 86 · Phase 4 11
First in 1997; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 231 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 333 across the 161 interventional studies, 595 across the 19 observational. Of the 116 that completed or were terminated, 70 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 182 have an industry lead sponsor. The 10 most frequent:
Banaras Hindu University is the lead sponsor of 21 studies on the registry; 2 are open to participants now.
Banaras Hindu University has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
15 of the studies in Breast Neoplasms with a site in India that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04906395Phase 3Tolmar Inc.Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | 2027-01-30 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05894239Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | 2027-05-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 182 studies in Breast Neoplasms with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Androgen Receptor is extensively expressed in BRCA and its role in the disease may differ depending upon molecular subtypes and stages. Androgen Receptor (AR) may act as an antagonist of estrogen receptor α (ERα), in ERα induced effect, whereas in the absence of estrogens, AR may act as an agonist, of ERα- promoting tumor. Thus, depending on the BRCA micro-environment, both agonists and antagonists of the AR have been suggested for therapeutic approaches.
The rate of AR positivity in breast cancer is about 60% to 80%. Biologically the AR pathway has cross talk with several other key signaling pathway, including the PI3K/Akt/mTOR and MAPK Pathways, and with other receptor, including estrogen receptor and human epidermal growth factor receptor-2. In clinical trials in patients with breast cancer, AR targeted therapies such as AR agonists, AR antagonists, PARP inhibitors, and PI3K inhibitors have shown promising results. The use of AR targeted therapies in conjunction with other agent has been investigated for overcoming resistance to AR focused treatments. Thus, the value of AR positivity as a prognostic marker has not been identified. Several retrospective clinical studies have shown that AR might be a prognostic or predictive factor in breast cancer. BRCA1 mutation accounts for the progress of hereditary breast cancers and is in connection with unique clinicopathological characteristics compared with sporadic breast cancers. The database is still evolving and newer mutation and their significance is being found every day. Also, there were several limitations to these previous studies. First, the cut-off for AR positivity was arbitrary. In most of the studies, the cut-off points were 1% or 10% and weren't enough to predict carcinoma survival. Moreover, quite 90% of the studies were conducted in non-Asian regions. Most of the studies involving Asian patients studied the prognostic role of AR in TNBC patients, with inconclusive results. There are only a few studies from Indian continents and none has correlated the AR expression with BRCA.
After the written inform consent in case of fresh recruitment the blood will be collected and tissue blocks will be obtained, use of already available blocks of patients who earlier participated in another study is also proposed.
(a) Samples will be stored for DNA study and will be frozen in liquid nitrogen and stored at -80 °C until further processing.
(samples will store in 10% formalin at room temperature (RT) for Immunohistochemistry
Patients with breast cancer and benign breast diseases
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with histologically proven breast cancer
Diagnostic Test: Androgen receptor status and BRCA mutation
Patients with benign breast diseases undergoing surgical resection
Diagnostic Test: Androgen receptor status and BRCA mutation
Androgen receptor status by IHC and germ line BRCA mutation
Receptor expression
Androgen receptor expression and its correlation with molecular subtypes of breast cancer
Time frame: 6 months
BRCA1 and BRCA2 mutations
BRCA mutations and its correlation with molecular subtypes of breast cancer
Time frame: 6 months
AR and BRCA
Correlation of Androgen receptor expression with BRCA mutation
Time frame: 6 months
Plan to share: Yes — On request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 3 months
Access criteria: on request
Ran from Jul 2021 to primary completion in Jul 2024, 36 months.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 36 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Banaras Hindu University